中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2014年
16期
2454-2455,2456
,共3页
食管肿瘤%多西他赛%顺铂
食管腫瘤%多西他賽%順鉑
식관종류%다서타새%순박
Esophageal neoplasms%Docetaxel%Cisplatin
目的:探讨周剂量多西他赛联合顺铂同步放疗在ⅢA、ⅢB期食管癌降期治疗中的应用效果。方法选取90例局部晚期食管鳞状细胞癌患者为研究对象,采用随机数字表法分为对照组(45例)和观察组(45例),观察比较两组临床治疗效果、不良反应发生率及治疗前后的血清肿瘤标志物水平变化。结果观察组总有效率(64.44%)明显高于对照组(46.67%)(χ2=3.97,P<0.05),且观察组血清CA199、CEA及SCC水平明显低于对照组(t=4.11、3.84、3.29,均P<0.05)。两组各类不良反应发生率差异均无统计学意义(均P>0.05)。结论多西他赛联合顺铂同步放疗在ⅢA、ⅢB期食管癌降期治疗中的应用效果较好,安全性高。
目的:探討週劑量多西他賽聯閤順鉑同步放療在ⅢA、ⅢB期食管癌降期治療中的應用效果。方法選取90例跼部晚期食管鱗狀細胞癌患者為研究對象,採用隨機數字錶法分為對照組(45例)和觀察組(45例),觀察比較兩組臨床治療效果、不良反應髮生率及治療前後的血清腫瘤標誌物水平變化。結果觀察組總有效率(64.44%)明顯高于對照組(46.67%)(χ2=3.97,P<0.05),且觀察組血清CA199、CEA及SCC水平明顯低于對照組(t=4.11、3.84、3.29,均P<0.05)。兩組各類不良反應髮生率差異均無統計學意義(均P>0.05)。結論多西他賽聯閤順鉑同步放療在ⅢA、ⅢB期食管癌降期治療中的應用效果較好,安全性高。
목적:탐토주제량다서타새연합순박동보방료재ⅢA、ⅢB기식관암강기치료중적응용효과。방법선취90례국부만기식관린상세포암환자위연구대상,채용수궤수자표법분위대조조(45례)화관찰조(45례),관찰비교량조림상치료효과、불량반응발생솔급치료전후적혈청종류표지물수평변화。결과관찰조총유효솔(64.44%)명현고우대조조(46.67%)(χ2=3.97,P<0.05),차관찰조혈청CA199、CEA급SCC수평명현저우대조조(t=4.11、3.84、3.29,균P<0.05)。량조각류불량반응발생솔차이균무통계학의의(균P>0.05)。결론다서타새연합순박동보방료재ⅢA、ⅢB기식관암강기치료중적응용효과교호,안전성고。
Objective To study the application effect of weekly dose of docetaxel combined with cisplatin and concurrent radiotherapy in the downstaging treatment of patients with esophageal carcinoma at at stage of ⅢA andⅢB.Methods 90 patients with locally advanced esophageal squamous cell carcinoma were the research object ,and they were divided into control group (PF group)45 cases and observation group (DP group)45 cases by using random number table method , then the clinical effect , adverse reaction rates and serum tumor markers before and after the treatment of two groups were analyzed ,and the analysis results were compared .Results The clinical effect of obser-vation group(64.44%)was better than those of control group (46.67%)(χ2 =3.97,P<0.05),and the serum tumor markers were lower than those of control group (t=4.11,3.84,3.29,all P<0.05),there were all significant differ-ences,while the various adverse reaction rates of two groups had no significant differences (all P>0.05).Conclusion The application effect of weekly dose of docetaxel combined with cisplatin and concurrent radiotherapy in the down -staging treatment of patients with esophageal carcinoma at at stage of ⅢA andⅢB is better ,and the safety is worth af-firmation.